The WTA has announced that tennis players will have to undergo genetic sex testing to play on the women's tour.
In an update to its eligibility policy, the WTA confirmed that athletes will have to undergo a one-time test for the SRY gene, which determines biological sex, coming into effect on Tuesday, with players facing disciplinary action should they refuse testing.
Previous WTA rules allowed the participation of transgender women provided their declared gender was female and they maintained a lower testosterone level for two years before competing.
There are no known transgender women on the WTA Tour or at any level of professional tennis.
"The updated policy is intended to provide a clear eligibility standard for participation in WTA tournaments," a statement from the WTA read.
"Eligibility to participate in WTA tournaments will be confirmed through a required, one-time screening process for the SRY gene.
"Player screening will begin in 2026, following all appropriate confidentiality and data privacy safeguards and concurrent with a comprehensive player engagement program.
"The WTA recognises that this is a sensitive and complex issue and is committed to treating all players with dignity and implementing the policy in a respectful and thoughtful way."
The change in regulations follows the enforcement of SRY testing for female athletes by World Athletics and World Boxing in 2025.
